In summary, the prevalence of cancers exhibiting hypoglycemic symptoms that are also associated with the secretion of IGF-II far surpasses the quantity and diversity of tumors linked to IGF-I expression or secretion, which aligns with the observations made in this particular case study. This evidence concerns the gene IGF1 and cancer.